Details of the Drug

General Information of Drug (ID: DMXMAJA)

Drug Name

Fosgonimeton

Synonyms

Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN]; UNII-H91OA9858J; H91OA9858J; 2093305-05-4; Fosgonimeton [USAN:INN]; ATH-1017; NDX-1017; WHO 11782; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; ATH-1017 FREE ACID; NDX-1017 FREE ACID; CHEMBL5095419; AKOS040757261; HY-132814; CS-0204081; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2/3	[1]
Parkinson disease	8A00.0	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C27H45N4O8P
Canonical SMILES: CCCCCC(=O)NC(CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)NC(C(C)CC)C(=O)NCCCCCC(=O)N
InChI: InChI=1S/C27H45N4O8P/c1-4-6-8-12-24(33)30-22(18-20-13-15-21(16-14-20)39-40(36,37)38)26(34)31-25(19(3)5-2)27(35)29-17-10-7-9-11-23(28)32/h13-16,19,22,25H,4-12,17-18H2,1-3H3,(H2,28,32)(H,29,35)(H,30,33)(H,31,34)(H2,36,37,38)/t19-,22-,25-/m0/s1
InChIKey: MBYDCPOKVKDSFD-JTJYXVOQSA-N

Cross-matching ID

PubChem CID: 156596375
TTD ID: DDBY18

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HGF/Met signaling pathway (HGF/Met pathway)	TTKA5LP	NOUNIPROTAC	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04886063) Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04831281) A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies. U.S.National Institutes of Health.
3	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.